AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The goal of this research study is to asses the safety and efficacy of the combination of
AGEN1423 and Balstilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for
the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after
at least one previous line of cancer therapy.
The names of the study drugs involved in this study are:
- AGEN1423
- Balstilimab
Participants will receive study treatment for about 2 years and will be followed for 1 year
after.